Oncolytics presents Phase 1b/2 Pelareorep data showing immune activation
Oncolytics announced single-cell sequencing results from an ABT- and pembrolizumab-combination trial revealing immune remodeling in multiple myeloma patients, supporting the company's therapeutic potential.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed